You are here

Home » Content

Fistülizan Tip Crohn Hastalığında İnfliksimab Kullanımı Sonrasında Yaygın Tüberküloz Enfeksiyonu Gelişen Bir Olgu – Reaktivasyon mu? IRIS mı?

A Case of Disseminated Tuberculosis After Infliximab Administration for Fistulating Crohn’s Disease – Is It a Reactivation or IRIS?

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
A single dose of infliximab administration for a patient with fistulating Crohn’s disease led to a fatal course after disseminated tuberculosis and fungal sepsis. Tumor Necrosis Factor–α antagonists are known to have administrative indication in romatoid arthritis, Crohn’s disease and psoriasis. However, many important complications may be seen during their usage, especially tuberculosis. In this report, the case was discussed, the literature was reviewed and main points with consensus were presented.
Bookmark/Search this post with
Abstract (Original Language): 
Fistülizan tip Crohn hastalığı nedeni ile tek doz infliksimab kullanılan bir hastada gelişen yaygın tüberküloz enfeksiyonu ve ciddi enfeksiyonlar sonrası fatal seyir izlenmişti. Tümör Nekrozis Faktör-α antagonistlerinin romatoid artrit, Crohn hastalığı ve psöriaziste kullanım endikasyonları vardır. Ancak bu ajanların kullanımına bağlı başta tüberküloz olmak üzere birçok önemli komplikasyon görülebilmektedir. Sunduğumuz olgunun ışığında oldukça güncel olan bu konudaki literatür tekrar değerlendirilmiş ve konsensus sağlanan görüşler sunulmuştur.
FULL TEXT (PDF): 
PDF icon arastirmax-fistulizan-tip-crohn-hastaliginda-infliksimab-kullanimi-sonrasinda-yaygin-tuberkuloz-enfeksiyonu-gelisen-bir-olgu-reaktivasyon-mu-iris-mi.pdf
  • 2
65-70
  • Turkish

REFERENCES

References: 

1. Stenson WF, Korzenik J. Inflammatory Bowel Disease. In:
Yamada T, Alpers DH, Kaplowitz N, Laine L, Owyang C,
Powell DW (eds). Textbook of Gastroenterology. 4
th
edition.
Philadelphia: Lippincott Williams & Wilkins; 2003. 1699-
1759.
2. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J
Aust 2005;183:205-8.
3. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present
DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ.
A short-term study of chimeric monoclonal antibody cA2 to
tumor necrosis factor alpha for Crohn's disease. Crohn's
Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
4. Wallis RS, Amir-Tahmasseb M, Ellner JJ. Induction of
interleukin 1 and tumor necrosis factor by mycobacterial
proteins: the monocyte western blot. Proc Natl Acad Sci U S
A 1990;87:3348-52.
5. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The
inducing role of tumor necrosis factor in the development of
bactericidal granulomas during BCG infection. Cell
1989;56:731-40.
6. Wallis RS. Reconsidering adjuvant immunotherapy for
tuberculosis. Clin Infect Dis 2005;41:201-8.
7. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S,
Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and
importance of antibody responses to infliximab after
maintenance or episodic treatment in Crohn's disease. Clin
Gastroenterol Hepatol 2004;2:542-53.
8. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L,
van Hogezand RA, Podolsky DK, Sands BE, Braakman T,
DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for
the treatment of fistulas in patients with Crohn's disease. N
Engl J Med 1999;340:1398-405.
9. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF,
Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson
A, Bao W, Hanauer SB. Comparison of scheduled and
episodic treatment strategies of infliximab in Crohn's disease.
Gastroenterology 2004;126:402-13.
10. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis
infection in patients with rheumatoid arthritis and the effect of
infliximab therapy. Arthritis Rheum 2004;50:372-9.
11. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J,
Schwieterman WD, Siegel JN, Braun MM. Tuberculosis
associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001;345:1098-104.
12. Molenaar ET, Bultink IE, Dijkmans BA, Lems WF.
Development of fatal tuberculosis in a patient with rheumatoid
arthritis after three years of treatment with infliximab:
comment on the article by Wolfe et al. Arthritis Rheum
2005;52:1334-6.
13. Uthman I, Sharara A. The usefulness of PPD testing in
inflammatory bowel disease patients before infliximab
therapy. Clin Gastroenterol Hepatol 2004;2:xxii.
14. Ormerod LP. Assessing risk and managing Mycobacterium
tuberculosis infection and disease in patients due to start antiTNFalpha treatment. Cytokine 2004;28:179-81.
15. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V,
Montero D, Pascual-Gomez E, Mola EM, Carreno L, Figueroa
M; BIOBADASER Group. Effectiveness of recommendations
to prevent reactivation of latent tuberculosis infection in
patients treated with tumor necrosis factor antagonists.
Arthritis Rheum 2005;52:1766-72.
16. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE,
Targan SR, Vasiliauskas EA. High incidence of anergy in
inflammatory bowel disease patients limits the usefulness of
PPD screening before infliximab therapy. Clin Gastroenterol
Hepatol 2004;2:309-13.
17. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC,
Nuermberger EL, Grosset J, Bishai WR. Dormancy phenotype
displayed by extracellular Mycobacterium tuberculosis within
artificial granulomas in mice. J Exp Med 2004;200:647-57.
18. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R,
Pohle M, Ducar C, Millard M, Mayanja-Kizza H, Whalen C,
Okwera A. A study of the safety, immunology, virology, and
microbiology of adjunctive etanercept in HIV-1-associated
tuberculosis. AIDS 2004;18:257-64.
19. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J,
Salavert M, Vidal R, Rodriguez Carballeira M, Garau J.
Paradoxical response to antituberculous therapy in infliximabtreated patients with disseminated tuberculosis. Clin Infect Dis
2005;40:756-9.

Thank you for copying data from http://www.arastirmax.com